Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

Earlier this year, the US Food and Drug Administration approved Lantidra, the first cell therapy for patients with type 1 diabetes. While this is a significant advance in the field, this month’s cover story explores how some researchers are debating whether it should be regulated like any other cell therapy or an organ transplant involving islets.

Also, in this issue, we present the first feature in a two-part investigation into the cost effectiveness of new therapies for haemophilia. While the innovative nature of these gene therapies is valuable, their million-dollar tags have presented challenges to health systems in charge of reimbursing them.

Don’t miss an exclusive interview delving into the use of artificial intelligence tools to recruit patients in clinical trials.

All this and the latest news and analysis on the pharmaceutical and biotech industry.

Manasi Vaidya, editor